Ocumetics Announces $2.5 Million Brokered LIFE Offering
Ocumetics Technology Corp., a Canadian company that makes new technology for vision, has announced a brokered private placement for up to $2.5 million. Centurion One Capital Corp. is in charge of the deal and will be the main agent and only bookrunner for the LIFE (Listed Issuer Financing Exemption) offering.
The corporation will try its best to sell up to 3,472,222 units for $0.72 apiece. Each unit has one common share and one warrant that can be used to buy a share for $0.90 for three years following closure.
Timeline For Agent Option And Offering
Ocumetics has also given Centurion One the chance to sell 520,833 more units, which may bring in an extra $375,000. You can use the option up to two business days before closure.
The offering is likely to end around December 11, 2025, but only if the TSX Venture Exchange and other necessary approvals are given. The deal will go through in British Columbia, Alberta, and Ontario under the LIFE exception. In the U.S. and other places, it will go through under certain registration exemptions.
Use Of Proceeds
The money from the IPO will go toward Ocumetics’ initial clinical studies on humans and other research and development work. Extra money will be used for general business needs and strategic operations to improve its lens technology.
The company aims to mostly use the money for clinical testing, although management may change how the money is spent based on new commercial prospects or changes in the law.
Recommended Article: China Robot Sets Guinness Record After 106 Kilometer Walk
Participation By Insiders
Some people who work for or are connected to Ocumetics are likely to take part in the offering. Multilateral Instrument 61-101 says that their engagement will be a “related party transaction.” The business thinks it should be able to get around the need for minority approval and valuation because fewer than 25% of Ocumetics’ market value should come from insiders.
This structure keeps the company in line with the law while letting important people help it flourish in the future.
Legal And Distribution Framework
The LIFE exemption will let the offering go ahead, which means that stocks may be sold in Canada without a mandatory hold period. Sales in the U.S. will follow any exemptions that apply under the U.S. Securities Act of 1933 and the laws of the states where they take place.
People who want to invest can find the formal Offering Document on the company’s SEDAR+ page and at www.ocumetics.com. The corporation wants investors to read the material before making any choices about investing.
About Ocumetics Technology Corp.
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a biotechnology company located in Calgary that works on improving eyesight correction methods. The business makes next-generation intraocular lenses that might make glasses or contact lenses unnecessary.
Its main technology is a bioengineered lens that fits into the eye’s native lens compartment. The lens seeks to provide you clear vision at all distances without any outside help by using the eye’s natural muscle movements to change the focus from far to near.
Moving Forward Toward Clinical Milestones
Ocumetics is getting ready for its first clinical studies on humans, which is a very important time for the company. This milestone will confirm years of study done before clinical trials and might speed up the process of bringing new products to market in the field of ophthalmology.
Ocumetics is becoming a leader in new technologies for restoring eyesight by working with scientific and financial partners like Centurion One.
A Plan For The Future
The LIFE offering through a broker shows that Ocumetics is dedicated to financing clinical advancement while keeping dilution to a minimum and protecting shareholder value. The organization wants to give patients and investors long-term advantages by combining financial discipline with medical innovation.
As Ocumetics moves closer to its 2026 goals, the LIFE offering is a big step toward bringing next-generation eye solutions to market and changing the way vision care is done in the future.
